160 related articles for article (PubMed ID: 33777762)
1. CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With
Yuan D; Li G; Yu L; Jiang Y; Shi Y; Chen Q; Ma X; Pham LV; Young KH; Deng M; Fang Z; Xu B
Front Oncol; 2021; 11():618908. PubMed ID: 33777762
[TBL] [Abstract][Full Text] [Related]
2. Orelabrutinib and venetoclax synergistically induce cell death in double-hit lymphoma by interfering with the crosstalk between the PI3K/AKT and p38/MAPK signaling.
Pan G; Zhong M; Yao J; Tan J; Zheng H; Jiang Y; Tang Y; Zhou H; Qin D; Yu X; Liu L; Li Z; Lin Z; Jiang Y; Xu B; Zha J
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5513-5529. PubMed ID: 36471019
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic synergy between tigecycline and venetoclax in a preclinical model of
Ravà M; D'Andrea A; Nicoli P; Gritti I; Donati G; Doni M; Giorgio M; Olivero D; Amati B
Sci Transl Med; 2018 Jan; 10(426):. PubMed ID: 29386360
[TBL] [Abstract][Full Text] [Related]
4. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.
Esteve-Arenys A; Valero JG; Chamorro-Jorganes A; Gonzalez D; Rodriguez V; Dlouhy I; Salaverria I; Campo E; Colomer D; Martinez A; Rymkiewicz G; Pérez-Galán P; Lopez-Guillermo A; Roué G
Oncogene; 2018 Apr; 37(14):1830-1844. PubMed ID: 29353886
[TBL] [Abstract][Full Text] [Related]
5. Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with
Uchida A; Isobe Y; Asano J; Uemura Y; Hoshikawa M; Takagi M; Miura I
Haematologica; 2019 Jul; 104(7):1417-1421. PubMed ID: 30523053
[TBL] [Abstract][Full Text] [Related]
6. Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOS.
de Jonge AV; Duetz C; Bruins WSC; Korst CLBM; Rentenaar R; Cosovic M; Eken M; Twickler I; Nijland M; van der Poel MWM; de Heer K; Klerk CPW; Strobbe L; Oosterveld M; Boersma R; Koene HR; Roemer MGM; van Werkhoven E; Chamuleau MED; Mutis T
Blood Adv; 2024 Mar; 8(5):1094-1104. PubMed ID: 38191686
[TBL] [Abstract][Full Text] [Related]
7. Advances in pathological understanding of high-grade B cell lymphomas.
Li S; Lin P; Medeiros LJ
Expert Rev Hematol; 2018 Aug; 11(8):637-648. PubMed ID: 29989509
[TBL] [Abstract][Full Text] [Related]
8. High-Grade B-Cell Lymphoma (HGBL) with
Tsai CC; Su YC; Bamodu OA; Chen BJ; Tsai WC; Cheng WH; Lee CH; Hsieh SM; Liu ML; Fang CL; Lin HT; Chen CL; Yeh CT; Lee WH; Ho CL; Lai SW; Tzeng HE; Hsieh YY; Chang CL; Zheng YM; Liu HW; Yen Y; Whang-Peng J; Chao TY
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33807449
[TBL] [Abstract][Full Text] [Related]
9. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors.
Li W; Gupta SK; Han W; Kundson RA; Nelson S; Knutson D; Greipp PT; Elsawa SF; Sotomayor EM; Gupta M
J Hematol Oncol; 2019 Jul; 12(1):73. PubMed ID: 31288832
[TBL] [Abstract][Full Text] [Related]
10. Apoptotic Blocks in Primary Non-Hodgkin B Cell Lymphomas Identified by BH3 Profiling.
Rys RN; Wever CM; Geoffrion D; Goncalves C; Ghassemian A; Brailovski E; Ryan J; Stoica L; Hébert J; Petrogiannis-Haliotis T; Dmitrienko S; Frenkiel S; Staiger A; Ott G; Steidl C; Scott DW; Sesques P; Del Rincon S; Mann KK; Letai A; Johnson NA
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33670870
[TBL] [Abstract][Full Text] [Related]
11. De novo acute lymphoblastic leukemia-like disease of high grade B-cell lymphoma with
Uchida A; Isobe Y; Uemura Y; Nishio Y; Sakai H; Kato M; Otsubo K; Hoshikawa M; Takagi M; Miura I
BMC Clin Pathol; 2017; 17():21. PubMed ID: 29151814
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
13. Establishment and characterization of a novel MYC/BCL2 "double-hit" diffuse large B cell lymphoma cell line, RC.
Pham LV; Lu G; Tamayo AT; Chen J; Challagundla P; Jorgensen JL; Medeiros LJ; Ford RJ
J Hematol Oncol; 2015 Oct; 8():121. PubMed ID: 26515759
[TBL] [Abstract][Full Text] [Related]
14. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW
J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716
[TBL] [Abstract][Full Text] [Related]
15. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
Landsburg DJ; Petrich AM; Abramson JS; Sohani AR; Press O; Cassaday R; Chavez JC; Song K; Zelenetz AD; Gandhi M; Shah N; Fenske TS; Jaso J; Medeiros LJ; Yang DT; Nabhan C
Cancer; 2016 Feb; 122(4):559-64. PubMed ID: 26565895
[TBL] [Abstract][Full Text] [Related]
16. Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas.
Cinar M; Rosenfelt F; Rokhsar S; Lopategui J; Pillai R; Cervania M; Pao A; Cinar B; Alkan S
Leuk Res; 2015 Jul; 39(7):730-8. PubMed ID: 25916698
[TBL] [Abstract][Full Text] [Related]
17. Transformation of marginal zone lymphoma into high-grade B-cell lymphoma expressing terminal deoxynucleotidyl transferase: A case report.
Fan ZM; Wu DL; Xu NW; Ye L; Yan LP; Li LJ; Zhang JY
World J Clin Cases; 2024 May; 12(15):2655-2663. PubMed ID: 38817237
[TBL] [Abstract][Full Text] [Related]
18. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
[TBL] [Abstract][Full Text] [Related]
19. Generation and characteristics of a novel "double-hit" high grade B-cell lymphoma cell line DH-My6 with
Kikuchi H; Higuchi T; Hashida Y; Taniguchi A; Kamioka M; Taguchi T; Yokoyama A; Murakami I; Fujieda M; Daibata M
Oncotarget; 2018 Sep; 9(71):33482-33499. PubMed ID: 30323893
[TBL] [Abstract][Full Text] [Related]
20. High-grade B-Cell Lymphoma With MYC, BCL2, and/or BCL6 Translocations/Rearrangements: Clinicopathologic Features of 51 Cases in a Single Institution of South China.
Zhang J; Weng Z; Huang Y; Li M; Wang F; Wang Y; Rao H
Am J Surg Pathol; 2020 Dec; 44(12):1602-1611. PubMed ID: 32991338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
